PROTEOR
Acquired by
ARDIAN / BNP PARIBAS DEVELOPPEMENT
PROTEOR acquired by ARDIAN / BNP PARIBAS DEVELOPPEMENT
Target
PROTEOR
Acquirer
ARDIAN / BNP PARIBAS DEVELOPPEMENT
Context
For the first time since its founding in 1913, Proteor has opened its capital to institutional investors through a primary Owner Buy-Out (OBO). Ardian Growth and BNP Paribas Développement have injected €24 million (a mix of convertible bonds and equity) to support the group's next phase of expansion. The founding Archambeaud family maintains clear majority control of the group. The strategic rationale for this primary round is to provide Proteor with the financial firepower to execute major international build-ups, specifically the $17 million acquisition of the US-based assets of Freedom Innovations. This deal transforms Proteor into a global player in the high-tech prosthetics market, integrating advanced micro-processor technologies and strengthening its footprint in North America.
This transaction is part of the Healthcare & Pharma industry, which currently tracks an average EBITDA multiple of 12.8x since the beginning of 2026, 1.8% increase compared to 2025. This data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.
-> Deep-dive in Healthcare & Pharma market trends
Target
Founded in 1913, PROTEOR is a world-class leader in the orthotics and prosthetics (O&P) market. The group specializes in high-tech orthopedic components (microprocessor knees, bionic feet) and custom-made medical devices. It operates a dual model combining manufacturing (R&D/Sales) and a large network of specialized care centers in France.
Ent. Value
LOGIN
Equity Value
LOGIN
Multiples Analysis
EV / Revenue
LOGIN
EV / EBITDA
LOGIN
EV / EBIT
LOGIN
Historical Financials (EUR)
Other operations with PROTEOR
| Date | Acquirer | Target | Country | Sector | Deal Context |
|---|---|---|---|---|---|
| 09/2025 | CREDIT MUTUEL EQUITY / EURAZEO / BPIFRANCE / BNP PARIBAS DEVELOPPEMENT | PROTEOR | FRANCE | Implants & Prosthetics | Proteor has orchestrated a secondary Owner Buy-Out (OBO Bis). The transaction allows Ardian Growth to exit its minority position, which it held since the primary OBO in 2021, realizing a return of approximately 3x money. The founding Archambeaud family remains the majority shareholder, continuing its 4th-generation leadership. The strategic rationale for this new round is to consolidate Proteor’s industrial activity and fund future international acquisitions, building on the successful integration of Freedom Innovations in the USA. The deal was supported by a diverse pool of national and regional banks providing senior debt. This partnership aims to strengthen Proteor’s position as a global integrated player, balancing its manufacturing expertise with its extensive network of orthopedic centers amidst a consolidating global market. |
mynth data is contributed by M&A / PE professionals and systematically cross-verified against private deal documents and official releases. All source materials are destroyed post-validation to guarantee data anonymity and compliance.